Rofecoxib-associated upper gastrointestinal bleed: A case report

被引：0
作者：
Freedman, GM [1 ]
Kreitzer, JM [1 ]
Badola, R [1 ]
机构：
[1] Mt Sinai Sch Med, Pain Management Serv, New York, NY 10029 USA
来源：
MOUNT SINAI JOURNAL OF MEDICINE | 2002年 / 69卷 / 1-2期
关键词：
rofecoxib; cyclo-oxygenase-2; inhibitor; nonsteroidal anti-inflammatory drug; peptic ulceration; upper gastrointestinal bleed;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To our knowledge, this is the first clinical report of a rofecoxib-associated upper gastrointestinal hemorrhage. We urge caution in prescribing rofecoxib to patients with risk factors for peptic ulcer disease and recommend limiting the dose to 25 mg per day for these patients.
引用
收藏
页码：105 / 106
页数：2
相关论文
共 12 条
  • [1] A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
    Day, R
    Morrison, B
    Luza, A
    Castaneda, O
    Strusberg, A
    Nahir, M
    Helgetveit, KB
    Kress, B
    Daniels, B
    Bolognese, J
    Krupa, D
    Seidenberg, B
    Ehrich, E
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (12) : 1781 - 1787
  • [2] Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
    Ehrich, EW
    Dallob, A
    De Lepeleire, I
    Van Hecken, A
    Riendeau, D
    Yuan, WY
    Porras, A
    Wittreich, J
    Seibold, JR
    De Schepper, P
    Mehlisch, DR
    Gertz, BJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) : 336 - 347
  • [3] Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67
  • [4] TOWARD AN EPIDEMIOLOGY OF GASTROPATHY ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE
    FRIES, JF
    MILLER, SR
    SPITZ, PW
    WILLIAMS, CA
    HUBERT, HB
    BLOCH, DA
    [J]. GASTROENTEROLOGY, 1989, 96 (02) : 647 - 655
  • [5] NONSTEROIDAL ANTIINFLAMMATORY DRUG-ASSOCIATED GASTROPATHY - INCIDENCE AND RISK FACTOR MODELS
    FRIES, JF
    WILLIAMS, CA
    BLOCH, DA
    MICHEL, BA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (03) : 213 - 222
  • [6] Hawkey C, 2000, ARTHRITIS RHEUM-US, V43, P370, DOI 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO
  • [7] 2-D
  • [8] A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
    Hunt, RH
    Bowen, B
    Mortensen, ER
    Simon, TJ
    James, C
    Cagliola, A
    Quan, H
    Bolognese, JA
    [J]. AMERICAN JOURNAL OF MEDICINE, 2000, 109 (03) : 201 - 206
  • [9] A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis
    Laine, L
    Harper, S
    Simon, T
    Bath, R
    Johanson, J
    Schwartz, H
    Stern, S
    Quan, H
    Bolognese, J
    [J]. GASTROENTEROLOGY, 1999, 117 (04) : 776 - 783
  • [10] Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
    Langman, MJ
    Jensen, DM
    Watson, DJ
    Harper, SE
    Zhao, PL
    Quan, H
    Bolognese, JA
    Simon, TJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (20): : 1929 - 1933
12